Ascendis Pharma A/S announced top-line results from Week 84 of the Company?s Phase 2 PaTH Forward Trial, a global trial evaluating the safety, tolerability, and efficacy of its investigational TransCon PTH product candidate in adult patients with hypoparathyroidism (HP). TransCon PTH is an investigational once-daily prodrug of parathyroid hormone (PTH) designed to restore physiologic levels of PTH 24 hours a day. The week 84 data showed that subjects treated with TransCon PTH had both mean serum calcium levels and urinary calcium excretion that remained stable and in the normal range and that most subjects (93%) continued to be free from taking active vitamin D and were taking < 600 mg/day of calcium supplements. After an initial screening and baseline assessment period, patients in the Phase 2 PaTH Forward Trial were randomized to blinded treatment with TransCon PTH at 15, 18, or 21 ?g/day or placebo for 4 weeks, followed by a switch to open label treatment, during which physicians could optimize dosing of TransCon PTH to meet individual treatment objectives. Key Findings at Week 84 of the Phase 2 PaTH Forward Trial: 58 out of the 59 original trial participants continued open-label treatment with TransCon PTH; Mean serum calcium levels remained stable and in the normal range; All study subjects discontinued active vitamin D supplements in the earliest weeks of the trial and have remained off it since then. In addition, 93% of study subjects were taking calcium supplements <600 mg/day Mean urinary calcium excretion remained stable and in the normal range; TransCon PTH was well-tolerated at all doses administered. No treatment-related serious or severe adverse events occurred, and no treatment-emergent adverse events (TEAEs) led to discontinuation of study drug.